Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34)

Journal of Bone and Mineral Research

Volumn 19, Issue 10, 2004, Pages 1661-1670

  Wang, Liming ^a   Quarles, L Darryl ^a   Spurney, Robert F ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Osteoblast; Osteoclast; Parathyroid hormone; Parathyroid hormone parathyroid related peptide; Receptor

Indexed keywords

CYCLIC AMP; G PROTEIN COUPLED RECEPTOR KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PROTEIN KINASE INHIBITOR; AMINO ACID; BETA ADRENERGIC RECEPTOR KINASE; BIOLOGICAL MARKER; CARRIER PROTEIN; CELL RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; DEOXYPYRIDINOLINE; GLYCOPROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; OSTEOPROTEGERIN; PARATHYROID HORMONE (1 34); PARATHYROID HORMONE (1-34); PARATHYROID HORMONE RECEPTOR; PEPTIDE FRAGMENT; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, MOUSE; TNFRSF11B PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE MASS; CALVARIA; CONTROLLED STUDY; CORTICAL BONE; ENZYME ACTIVATION; ENZYME INHIBITION; FEMUR SHAFT; HORMONE ACTION; LUMBAR SPINE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PROTEIN EXPRESSION; TRABECULAR BONE; TRANSGENE; AGING; ANIMAL; BONE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE; URINE;

AGING; AMINO ACIDS; ANIMALS; BETA-ADRENERGIC RECEPTOR KINASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CARRIER PROTEINS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GLYCOPROTEINS; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, PARATHYROID HORMONE; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER;

EID: 21644439556     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.040708     Document Type: Article

References (49)

1. Eastell R 1998 Treatment of postmenopausal osteoporosis. N Engl J Med 338:736-745.
2. Rodan GA, Martin TJ 2000 Therapeutic approaches to bone diseases. Science 289:1508-1514.
3. Quarles LD, Siddhanti SR 1996 Guanine nucleotide binding-protein coupled signaling pathway regulation of osteoblast-mediated bone formation. J Bone Miner Res 11:1375-1383.
4. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM 1994 Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331:1618-1623.
5. 2 on cortical bone turnover in adult dogs: A histomorphometric study. Bone 8:363-373.
6. Liu CC, Kalu DN, Salerno I, Echon R, Hollis BW, Ray M 1991 Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone. J Bone Miner Res 6:1071-1079.
7. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OM, Courpron P, Edouard C, Klenerman L, Neer RM, Slock D, Vismans FJFE, Potts JT 1980 Anabolic effect of human parathyroid hormone fragment on trabecular bone in involution osteoporosis: A multicentre trial. BMJ 280:1340-1344.
8. Dohlman HG, Thorner J, Caron MG, Lefkowitz RJ 1991 Model systems for the study of seven-transmembrane-segment receptors. Annu Rev Biochem 60:653-688.
9. Lefkowitz RJ 1993 G-protein-coupled receptor kinases. Cell 74: 409-412.
10. Premont RT, Inglese J, Lefkowitz RJ 1995 Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J 9:175-182.
11. Ferguson SSG, Barak LS, Zhang J, Caron MG 1996 G-protein-coupled receptor regulation: Role of G-protein-coupled receptor kinases and arrestins. Can J Physiol Pharmacol 74:1095-1110.
12. Kohout TA, Lefkowitz RJ 2003 Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 63:9-18.
13. Flannery PJ, Spurney RF 2001 Domains of the parathyroid hormone (PTH) receptor required for regulation by G protein-coupled receptor kinases. Biochem Pharmacol 62:1047-1058.
14. Dicker F, Quitterer U, Winstel R, Honold K, Lohse M 1999 Phosphorylation-independent inhibition of parathyroid hormone receptor signaling by G protein-coupled receptor kinases. Proc Natl Acad Sci USA 96:5476-5481.
15. Malecz N, Bambino T, Bencsik M, Nissenson RA 1998 Identification of phosphorylation sites in the G protein-coupled receptor for parathyroid hormone. Receptor phosphorylation is not required for agonist-induced internalization. Mol Endocrinol 12:1846-1856.
16. Boekhoff I, Inglese J, Schleicher S, Koch WJ, Lefkowitz RJ, Breer H 1994 Olfactory desensitization requires membrane targeting of receptor kinase mediated by βγ-subunits of heterotrimeric G proteins. J Biol Chem 269:37-40.
17. βγ-mediated signaling. J Biol Chem 269:6193-6197.
18. Koch WJ, Rockman H, Samama P, Hamilton R, Bond RA, Milano CA, Lefkowitz RJ 1995 Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor. Science 268:1350-1353.
19. Koch WJ, Inglese J, Stone C, Lefkowitz RJ 1993 The binding site for the βγ subunits of heterotrimeric G proteins on the β-adrenergic receptor kinase. J Biol Chem 268:8256-8260.
20. Spurney RF, Flannery PJ, Garner SC, Athirakul K, Liu S, Guilak F, Quarles LD 2002 Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. J Clin Invest 109:1361-1371.
21. Takahashi N, Udagawa N, Suda T 1999 A new member of the tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 256:229-255.
22. Canalis E 2003 Osteogenic growth factors. In: Favus MJ (ed.) Primer of Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed. Cadmus Professional Communications, New York, NY, USA, pp. 28-32.
23. Strewler GL 2000 The physiology of parathyroid hormone-related protein. N Engl J Med 342:177-185.
24. Amizuka N, Karaplis AC, Henderson JE, Warshawsky H, Lipman ML, Matsuki Y, Ejiri S, Tanaka M, Izumi N, Ozawa H, Goltzman D 1996 Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev Biol 175:166-176.
25. Pan LC, Crawford DT, Simmons HA, McCurdy SP, Nguyen MT, Tilley S, Koller BH, Ke HZ 1998 Mouse lines lacking EP2 and EP4 prostaglandin receptor subtypes exhibit different bone phenotypes. Bone 23(Suppl):S168.
26. Li M, Healy DR, Li Y, Simmons HA, Crawford DT, Ke HZ, Pan LC, Brown TZ, Thompson DD 2003 Osteopenia and impaired fracture healing in the EP4 receptor knockout mice. J Bone Miner Res 18:5168.
27. Miao D, He B, Karaplis AC, Goltzman D 2002 Parathyroid hormone is essential for normal fetal bone formation. J Clin Invest 109:1173-1182.
28. Miao D, Li J, Xue Y, Su H, Karaplis AC, Goltzman D 2003 PTHrP haploinsufficiency reduces bone volume in postnatal PTH deficient mice. J Bone Miner Res 18:S2;S2.
29. Corral DA, Amling M, Priemel M, Loyer E, Fuchs S, Ducy P, Baron R, Karsenty G 1998 Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci USA 95:13835-13840.
30. Salomon Y, Londos C, Rodbell M 1974 A highly sensitive adenylate cyclase assay. Anal Biochem 58:541-548.
31. Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, Beamer W, Majumdar S, Halloran BP 2002 Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 17:1570-1578.
32. Sakai A, Sakata T, Ikeda S, Uchida S, Okazaki R, Norimura T, Hori M, Nakamura T 1999 Intermittent administration of human parathyroid hormone (1-34) prevent immobilization-related bone loss by regulating bone marrow capacity for bone cells in ddY mice. J Bone Miner Res 14:1691-1699.
33. Jilka RL, Weinstein RS, Bellido T, Robertson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104: 439-446.
34. Iida-Klein A, Zhou H, Lu SS, Bevine LR, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R 2002 Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 17:808-816.
35. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols and units. J Bone Miner Res 2:595-610.
36. Wallenstein S, Zucker CL, Fleiss JL 1980 Some statistical methods useful in circulation research. Circ Res 47:1-12.
37. 2 in human bone marrow stromal cells. Biochem Biophys Res Commun 247:338-341.
38. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, McClure D, Seno DG, Sekhar S, Martin TJ 2000 In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 15:863-871.
39. Lee S, Lorenzo JA 1999 Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 140:3552-3561.
40. Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC 1998 Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest 101:1942-1950.
41. Hausdorff WP, Caron MG, Lefkowitz RJ 1990 Turning off the signal: Desensitization of the β-adrenergic receptor function. FASEB J 4:2881-2889.
42. Qi H, Li M, Wronski TJ 1995 A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J Bone Miner Res 10:948-955.
43. Tada K, Yammauro T, Okumura H, Kasai R, Takahashi H 1990 Restoration of axial and appendicular bone volumes by h-PTH(1-34) in parathyroidectomized and osteopenic rats. Bone 11:163-169.
44. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 3444:1434-1443.
45. Riggs BL, Melton LJ III 1992 The prevention and treatment of osteoporosis. N Engl J Med 327:620-627.
46. Dobnig H, Turner RT 1995 Evidence that intermitent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632-3638.
47. Turner RT, Evans GL, Cavolina JM, Halloran B, Morey-Holton E 1998 Programmed administration of parathyroid hormone increases bone formation and reduces bone loss in hindlimb-unloaded ovarietomized rats. Endocrinology 139:4086-4091.
48. Li W, Okada Y, Pilbeam CC, Lorenzo JA, Kennedy CR, Breyer RM, Raiz LG 2000 Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 141:2054-2061.
49. Suzuki J, Ikeda T, Kuroyama H, Seki S, Kasai M, Utsuyama M, Tatsumi M, Uematsu H, Hirokawa K 2004 Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem Biophys Res Commun 314:1021-1027.